Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Solta Medical Inc.

Division of Bausch Health Companies Inc.
www.solta.com

Latest From Solta Medical Inc.

Appointments: ThermiGen, ReForm Biologics, Hookipa Biotech and Faron

This week’s roundup includes high-level appointments by Almirall, Hookipa Biotech and RXi Pharmaceuticals, in addition to CEO appointments by Karolinska Development and ReForm Biologics and various board announcements by companies including Faron and Redx.

Appointments BioPharmaceutical

Valeant’s Pearson Is Out, As Hunt Begins For A CEO To Right The Wrongs

Valeant has begun the search for a new CEO, who will be charged with turning around the troubled company and likely divesting some assets. The company also calls out former CFO Howard Schiller for “improper conduct.”

BioPharmaceutical Business Strategies

Deals Shaping The Medical Industry, June 2014

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced April through May 2014.

BioPharmaceutical Consumer

Foresite Capital Raises $300M Fund Focused On Life Sciences

San Francisco-based VC also is an investor in a $200 million Series DD funding for type 2 diabetes-focused Intarcia Therapeutics. Foresite will use the same investment strategy for its second fund, seeking late-stage investments in proven technologies with strong management and promising market positions.

United States Business Strategies
See All

Company Information

UsernamePublicRestriction

Register